Tags

Type your tag names separated by a space and hit enter

Labeling for oral and rectal over-the-counter drug products containing aspirin and nonaspirin salicylates; Reye's Syndrome warning. Final rule.
Fed Regist. 2003 Apr 17; 68(74):18861-9.FR

Abstract

The Food and Drug Administration (FDA) is issuing a final rule to amend its regulations to revise the Reye's syndrome warning required for oral and rectal over-the-counter (OTC) human drug products containing aspirin and to require a warning on OTC drug products containing nonaspirin salicylates as active ingredients. The revised warning will inform consumers of the symptoms of Reye's syndrome and advise that aspirin and nonaspirin salicylate drug products should not be given to children or teenagers who have or are recovering from chicken pox or flu-like symptoms. This final rule also finalizes FDA's notice of proposed rulemaking to require a Reye's syndrome warning for orally administered OTC drug products for relief of symptoms associated with overindulgence in food and drink (overindulgence drug products) that contain bismuth subsalicylate that published in the Federal Register of May 5, 1993 (58 FR 26886). FDA is issuing this final rule after considering public comment on the agency's notices of proposed rulemaking and all relevant data and information that have come to the agency's attention.

Authors

No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

12701599

Citation

Food and Drug Administration, HHS. "Labeling for Oral and Rectal Over-the-counter Drug Products Containing Aspirin and Nonaspirin Salicylates; Reye's Syndrome Warning. Final Rule." Federal Register, vol. 68, no. 74, 2003, pp. 18861-9.
Food and Drug Administration, HHS. Labeling for oral and rectal over-the-counter drug products containing aspirin and nonaspirin salicylates; Reye's Syndrome warning. Final rule. Fed Regist. 2003;68(74):18861-9.
Food and Drug Administration, HHS. (2003). Labeling for oral and rectal over-the-counter drug products containing aspirin and nonaspirin salicylates; Reye's Syndrome warning. Final rule. Federal Register, 68(74), 18861-9.
Food and Drug Administration, HHS. Labeling for Oral and Rectal Over-the-counter Drug Products Containing Aspirin and Nonaspirin Salicylates; Reye's Syndrome Warning. Final Rule. Fed Regist. 2003 Apr 17;68(74):18861-9. PubMed PMID: 12701599.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Labeling for oral and rectal over-the-counter drug products containing aspirin and nonaspirin salicylates; Reye's Syndrome warning. Final rule. A1 - ,, PY - 2003/4/19/pubmed PY - 2003/5/6/medline PY - 2003/4/19/entrez SP - 18861 EP - 9 JF - Federal register JO - Fed Regist VL - 68 IS - 74 N2 - The Food and Drug Administration (FDA) is issuing a final rule to amend its regulations to revise the Reye's syndrome warning required for oral and rectal over-the-counter (OTC) human drug products containing aspirin and to require a warning on OTC drug products containing nonaspirin salicylates as active ingredients. The revised warning will inform consumers of the symptoms of Reye's syndrome and advise that aspirin and nonaspirin salicylate drug products should not be given to children or teenagers who have or are recovering from chicken pox or flu-like symptoms. This final rule also finalizes FDA's notice of proposed rulemaking to require a Reye's syndrome warning for orally administered OTC drug products for relief of symptoms associated with overindulgence in food and drink (overindulgence drug products) that contain bismuth subsalicylate that published in the Federal Register of May 5, 1993 (58 FR 26886). FDA is issuing this final rule after considering public comment on the agency's notices of proposed rulemaking and all relevant data and information that have come to the agency's attention. SN - 0097-6326 UR - https://www.unboundmedicine.com/medline/citation/12701599/Labeling_for_oral_and_rectal_over_the_counter_drug_products_containing_aspirin_and_nonaspirin_salicylates L2 - https://www.govinfo.gov/content/pkg/FR-2003-04-17/pdf/03-9382.pdf DB - PRIME DP - Unbound Medicine ER -